Title:
SENSITIZATION OF CANCER CELLS BY THE REMOVAL OF SOLUBLE TUMOR NECROSIS FACTOR RECEPTORS
Document Type and Number:
WIPO Patent Application WO/2013/179143
Kind Code:
A3
Abstract:
The present invention relates to a molecule binding to soluble tumor necrosis factor receptor (sTNFR) for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent, wherein said molecule is immobilized on a solid support that is contacted with a body fluid of said patient. Furthermore, the present invention refers to a method for sensitizing a tumor cell and to a body fluid from which sTNFR has been removed for use in a method for sensitizing a tumor cell in a patient to a treatment with a chemotherapeutic agent. Moreover, the present invention refers to a chemotherapeutic agent for use in a method for treating a tumor in a patient for sensitizing a tumor cell of said tumor in said patient to a treatment with said chemotherapeutic agent.
Inventors:
BERG SABINE (DE)
WIESNER PETER (DE)
WIESNER PETER (DE)
Application Number:
PCT/IB2013/001583
Publication Date:
May 01, 2014
Filing Date:
May 31, 2013
Export Citation:
Assignee:
BIOPHERESIS TECHNOLOGIES INC (US)
International Classes:
A61M1/36; C07K16/28
Domestic Patent References:
| WO2012163544A1 | 2012-12-06 | |||
| WO2005107802A2 | 2005-11-17 | |||
| WO1999061085A2 | 1999-12-02 | |||
| WO2001037873A2 | 2001-05-31 |
Other References:
MEREDITH LENTZ ET AL: "Reduction of Plasma Levels of Soluble Tumor Necrosis Factor and Interleukin-2 Receptors by Means of a Novel Immunoadsorption Column", THERAPEUTIC APHERESIS AND DIALYSIS, vol. 12, no. 6, 1 December 2008 (2008-12-01), pages 491 - 499, XP055001372, ISSN: 1744-9979, DOI: 10.1111/j.1744-9987.2008.00640.x
ROBBERT G VAN DER MOST ET AL: "Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 58, no. 8, 4 December 2008 (2008-12-04), pages 1219 - 1228, XP019706344, ISSN: 1432-0851
ROBBERT G VAN DER MOST ET AL: "Tumor eradication after cyclophosphamide depends on concurrent depletion of regulatory T cells: a role for cycling TNFR2-expressing effector-suppressor T cells in limiting effective chemotherapy", CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN, DE, vol. 58, no. 8, 4 December 2008 (2008-12-04), pages 1219 - 1228, XP019706344, ISSN: 1432-0851
Attorney, Agent or Firm:
OSBORNE, David, W. (North & Western LLPP.O. Box 121, Sandy UT, US)
Download PDF:
Previous Patent: TIBIAL TUBEROSITY ADVANCEMENT CAGE FOR ACL INJURIES
Next Patent: CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEINOPATHIC DISEASES
Next Patent: CHEMICAL SUPPRESSORS OF NEUROTOXICITY IN SYNUCLEINOPATHIC DISEASES